RT info:eu-repo/semantics/article
T1 An integrative look at SARS-CoV-2 (Review)
A1 Ortega Núñez, Miguel Ángel
A1 Fraile Martínez, Óscar
A1 García Montero, Cielo
A1 García Gallego, Sandra
A1 Sánchez Trujillo, Lara
A1 Torres Carranza, Diego
A1 Álvarez de Mon González, Miguel Ángel
A1 Pekarek, Leonel
A1 García Honduvilla, Natalio Antonio
A1 Buján Varela, María Julia Araceli
A1 Álvarez de Mon Soto, Melchor
A1 Asúnsolo del Barco, Ángel
A1 Torre Escuredo, Basilio José de la
K1 SARS-CoV-2
K1 COVID-19
K1 coronavirus
K1 therapy
K1 vaccine
K1 Chemistry
K1 Química
K1 Medicina
K1 Medicine
AB SARS‑CoV‑2 is a newly discovered member of the betacoronaviruses and the etiological agent of the disease COVID‑19. SARS‑CoV‑2 is responsible for the worldwide pandemic which has been taking place in 2020, and is causing a markedly higher number of infections and deaths compared to previous coronaviruses, such as SARS‑CoV or MERS‑CoV. Based on updated scientific literature, the present review compiles the most relevant knowledge of SARS‑CoV‑2, COVID‑19 and the clinical and typical responses that patients have exhibited against this virus, discussing current and future therapies, and proposing strategies with which to combat the disease and prevent a further global threat. The aggressiveness of SARS‑CoV‑2 arises from its capacity to infect, and spread easily and rapidly through its tight interaction with the human angiotensin‑converting enzyme 2 (ACE‑2) receptor. While not all patients respond in a similar manner and may even be asymptomatic, a wide range of manifestations associated with COVID‑19 have been described, particularly in vulnerable population groups, such as the elderly or individuals with other underlying conditions. The proper function of the immune system plays a key role in an individual's favorable response to SARS‑CoV‑2 infection. A hyperactivated response, on the contrary, could account for the more severe cases of COVID‑19, and this may finally lead to respiratory insufficiency and other complications, such as thrombotic or thromboembolic events. The development of novel therapies and vaccines designed to control and regulate a proper immune system response will be key to clinical management, prevention measures and effective population screening to attenuate the transmission of this novel RNA virus.
SN 1107-3756
YR 2020
FD 2020-12-22
LK http://hdl.handle.net/10017/46750
UL http://hdl.handle.net/10017/46750
LA eng
DS MINDS@UW
RD 24-abr-2024